Nick Roehrick has accepted a one-year suspension from USADA after failing an out-of-competition urine test conducted on Aug. 8.
The UFC light heavyweight tested positive for clomiphene and its metabolite, 4-hydroxyclomiphene. Roehrick’s sanction is retroactive to Aug. 17, the date his provisional suspension was imposed. Per USADA:
Clomiphene is not approved by the U.S. Food & Drug Administration (FDA) for use in the male population, meaning such off-label clinical use has not been thoroughly studied for safety and efficacy. Clomiphene also indirectly promotes the secretion of testosterone. Increasing testosterone, especially when combined with strength training, has been demonstrated to increase fat-free mass, muscle size, and strength in males, potentially leading to performance enhancement in sport.
Roehrick came up short in his Octagon debut, falling to Jared Cannonier at “The Ultimate Fighter 25” finale on July 7. The Orlando, Fla., native is 7-1 as a professional overall.